| Title |
Orphan drugs policies: a suitable case for treatment
|
|---|---|
| Published in |
HEPAC Health Economics in Prevention and Care, January 2014
|
| DOI | 10.1007/s10198-014-0560-1 |
| Pubmed ID | |
| Authors |
Michael Drummond, Adrian Towse |
| Abstract |
Current orphan drug policies are unsatisfactory when viewed from almost all perspectives. Patients find that, although therapies are available for many rare conditions, access to care is sometimes restricted. Pharmaceutical manufacturers have responded to the incentives for research embodied in orphan drug legislation, only to find that funds are not made available to pay for therapies once developed. Those funding health care find that most orphan drugs do not justify funding based on standard value for money criteria, yet that they face political problems if they fail to provide funding for therapy. |
X Demographics
The data shown below were collected from the profiles of 20 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 15% |
| United Kingdom | 2 | 10% |
| Canada | 2 | 10% |
| Norway | 1 | 5% |
| Australia | 1 | 5% |
| Spain | 1 | 5% |
| Brazil | 1 | 5% |
| Unknown | 9 | 45% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 16 | 80% |
| Scientists | 3 | 15% |
| Practitioners (doctors, other healthcare professionals) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 173 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Canada | 1 | <1% |
| Austria | 1 | <1% |
| Unknown | 170 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 37 | 21% |
| Student > Master | 30 | 17% |
| Other | 15 | 9% |
| Student > Bachelor | 14 | 8% |
| Student > Doctoral Student | 11 | 6% |
| Other | 24 | 14% |
| Unknown | 42 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 22% |
| Pharmacology, Toxicology and Pharmaceutical Science | 20 | 12% |
| Economics, Econometrics and Finance | 18 | 10% |
| Social Sciences | 15 | 9% |
| Biochemistry, Genetics and Molecular Biology | 6 | 3% |
| Other | 27 | 16% |
| Unknown | 49 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 March 2019.
All research outputs
#1,696,308
of 25,374,647 outputs
Outputs from HEPAC Health Economics in Prevention and Care
#57
of 1,303 outputs
Outputs of similar age
#18,983
of 320,076 outputs
Outputs of similar age from HEPAC Health Economics in Prevention and Care
#1
of 38 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,303 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,076 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.